Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: The Industrial Rotation

    In this Economics Weekly, Richard de Chazal looks at what the financial market and real economic data are telling us about the durability of the rotation toward industrials as well as where this recovery could hit major roadblocks.

    Read more

  • Top Wall Street Analysts

    TipRanks acknowledged seven William Blair equity research analysts among the top 10%, reflecting their ability to outperform their peers with expertise and stock selection.

    Read more

  • The Case for Small- and SMID-Cap Value

    Members of our U.S. value equity team explain why small- and SMID-cap value stocks—marked by valuation inefficiencies, quality fundamentals, and market dislocations—may offer compelling opportunities for active, long-term investors.

    Watch the video
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures